Since the 1940s male pattern baldness (MPB) has been recognized by Dermatologist in Delhi as an androgen-dependent condition. Eventually, dihydrotestosterone (DHT) was established as the key androgen involved in (a) the shortening of the anagen growth phase, and (b) the progressive follicular miniaturization that accompanies each hair growth, loss, and regrowth cycle – the two hallmarks of MPB. The role of androgens in female pattern hair loss (FPHL), however, for Skin Specialist it remains uncertain and prevents us from defining pattern hair loss in both genders as androgenetic alopecia (AGA). Both MPB and FPHL are often familial and have a polygenetic inheritance pattern. In Hair Clinic in Delhi treats these patients successfully.
Specific Investigations for Females
- Work – up for polycystic ovarian syndrome
- Free testosterone, DHT serum levels
- Serum ferritin
- Thyroid function tests
- 4 mm diameter scalp biapsy
Medical Therapies by Hair Specialist in Delhi
- Topical minoxidil ( 2% & 5%) once or twice daily
- Finasteride 1 mg once a day
- Spironolactone 100 to 200 mg/day
- Cyproterone acetate 50-100 mg/day for days 5 to 10 of menstrual cycle, combined with oral estinyl 20 mg twice daily, days 5-24 of cycle
Hair loss in women. Using a case vignette, this reviw emphasizes effective evaluation of FPHL through history talking and clinical findings. Characteristics of non- scarring alopecia and investigative strategies are highlighted.
A randomized, placebo-controlled trial of 5% and 2% topical monoxidil solutions in the treatment of female pattern hair loss. Treatment with both 5% & 2% minoxidil resulted in significantly enhanced hair counts and investigator assessment versus treatment with placebo after 48 weeks. Although patient perception of hair growth was statistically superior in the 5% versus the 2% treatment, no unequivacal dose-dependent improvement was demostrated in either non-vellus hair count or investigator-rated hair density. Interestingly, the peak efficacy in both treatment groups was noted at the 16-week evaluation, with counts beginning to decline progressively at weeks 32 & 48.
Treatment of female pattern hair loss with oral anti-androgens. The results of this study of 80 women treated with either spironolactone or cyproterone acetate indicated a positive effect with treatment. In the treatment group 44% of women showed regrowth, 44% demonstrated no progression of hair loss, and 12% countinued with proregressive hair loss. Women with more severe beseline FPHL were more likely to be responders. This study does not compare results with a placebo group, nor were the investigators blinded.